Research Use Only - Not for human consumption. 18+ only.
Research CompoundGrowth Hormone SecretagoguesOral

Tabimorelin

An oral ghrelin mimetic that stimulates GH release and appetite. Research stage with potential for cachexia treatment.

Research Status

Research Compound

Early Research

For research purposes only. Not approved for human use. Not medical advice.

Research Areas

Stimulates growth hormone secretion
Increases appetite and food intake
May improve muscle mass and body composition
Potential cachexia and wasting syndrome treatment
Oral bioavailability for convenient administration
Ghrelin receptor agonist activity

Side Effects

Increased appetite and food intake
CommonMild

Expected pharmacological effect; may be therapeutic in cachexia but problematic in obesity. Manage by monitoring caloric intake and food choices.

Increased cortisol levels
UncommonModerate

Ghrelin agonists may transiently elevate cortisol; monitor if using long-term. Baseline and periodic cortisol testing recommended.

Nausea or gastrointestinal discomfort
UncommonMild

May occur with oral administration. Take with food if GI upset develops; usually resolves with continued use.

Headache
UncommonMild

Reported in some users; typically mild and self-resolving. Ensure adequate hydration.

Fluid retention and edema
RareModerate

GH secretagogues may increase water retention. Monitor weight and lower extremity swelling; discontinue if significant edema develops.

Hyperglycemia or impaired glucose tolerance
RareModerate

GH excess can antagonize insulin action. Monitor fasting glucose and HbA1c, especially in those with metabolic risk factors.

Joint or muscle aches
RareMild

May occur with rapid GH elevation. Usually mild and transient.

Carpal tunnel syndrome (chronic use)
RareModerate

Long-term GH excess can cause carpal tunnel; monitor for wrist pain or paresthesias with extended use.

Dosing Reference

ParameterValue
Dose range5-25 mcg
Frequency1-3x daily
TimingBefore meals or before bed
RouteOral

Oral administration. Research compound — not approved for human use. Start at lower end (5 mcg) and titrate based on response. Take with or without food, though timing relative to meals may affect appetite stimulation.

Research disclaimer

Figures drawn from published research literature and community logs. Not clinical recommendations. Consult a qualified professional. Research use only.

Reconstitution Guide

Do not use saline or bacteriostatic saline — use only bacteriostatic water for reconstitution

Do not shake the vial vigorously; gentle swirling prevents peptide degradation

Discard immediately if the solution appears cloudy, discolored, or contains visible particles

Use within 30 days of reconstitution when stored at 2–8°C

Do not freeze the reconstituted solution; freezing may denature the peptide

Use the PeptideVolt reconstitution calculator for your exact concentration

Use the PeptideVolt reconstitution calculator for your exact concentration

Molecular and Pharmacological Data

Tabimorelin is an oral ghrelin receptor agonist (mimetic) that binds to the growth hormone secretagogue receptor (GHSR-1a) on pituitary somatotroph cells and hypothalamic neurons. This activation stimulates the release of growth hormone and increases appetite signaling through central ghrelin pathways. The compound was designed to provide oral bioavailability for GH secretion and appetite stimulation, with potential applications in cachexia, wasting syndromes, and age-related GH decline.

GHSR-1a Activation

Tabimorelin binds to growth hormone secretagogue receptor type 1a on pituitary somatotrophs, triggering GH release via increased intracellular calcium and IP3 signaling

Hypothalamic GH-RH Stimulation

Activation of GHSR-1a on hypothalamic neurons increases GH-releasing hormone (GH-RH) secretion, which synergizes with direct pituitary effects

Appetite Regulation

Ghrelin receptor agonism activates orexigenic neurons in the arcuate nucleus, increasing appetite and food intake via NPY/AgRP pathways

Somatostatin Inhibition

GHSR-1a signaling suppresses somatostatin release from hypothalamic neurons, removing tonic GH inhibition

  • Tabimorelin is a non-peptide small-molecule ghrelin mimetic with oral bioavailability
  • Binds selectively to GHSR-1a (growth hormone secretagogue receptor type 1a)
  • Stimulates pulsatile GH secretion similar to endogenous ghrelin
  • Increases appetite and food intake through central ghrelin signaling
  • Designed to address GH deficiency and cachexia in research settings
  • Oral administration avoids injection-related complications

Track your Tabimorelin research

Free account. No credit card required.

Start Free

Browse the Research Library

40+ peptide profiles with mechanism summaries, dosing data, and reconstitution guides.

View all peptides

Research Use Only. All content on this page is provided for informational and educational purposes related to scientific research. Tabimorelin is not approved for human use by the FDA or any equivalent regulatory body. This is not medical advice. Do not use any substance discussed here for therapeutic, diagnostic, or preventative purposes. Consult a qualified healthcare professional before making any health-related decisions. The Peptide Volt does not endorse the use of any research chemicals. 18+ only.